Corazza Elisa, Pizzi Asia, Parolin Carola, Giordani Barbara, Abruzzo Angela, Bigucci Federica, Cerchiara Teresa, Luppi Barbara, Vitali Beatrice
Drug Delivery Research Laboratory, Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Via San Donato 19/2, 40127 Bologna, Italy.
Beneficial Microbes Laboratory, Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Via San Donato 19/2, 40127 Bologna, Italy.
Pharmaceutics. 2024 Nov 18;16(11):1470. doi: 10.3390/pharmaceutics16111470.
Due to the high frequency and severity of upper respiratory bacterial infections, probiotics could offer a new medical approach. We explored the antibacterial and anti-inflammatory properties of the new strain BIA and formulated a nasal spray. BIA was isolated from orange peel and taxonomically identified through 16S rRNA gene sequencing. Its antibacterial activity was tested against , , , , and , while anti-inflammatory potential was evaluated by Griess assay. BIA genome was fully sequenced and analyzed to assess its safety. BIA was formulated in a freeze-dried matrix, containing prebiotics and cryoprotectants, to be reconstituted with a polymer solution. Solutions containing two types of hydroxypropyl methylcellulose (HPMC) and hyaluronic acid were evaluated as resuspending media and compared in terms of pH, viscosity, and mucoadhesion ability. The biological activity of BIA formulated as nasal spray was verified together with the stability of the selected formulations. BIA inhibited human pathogens' growth and showed anti-inflammatory activity and a safe profile. In the best-performing formulation, the probiotic is lyophilized in 10% fructooligosaccharides, 0.1% ascorbic acid, and 0.5% lactose and reconstituted with HPMC high viscosity 1% /. This composition ensured the probiotic's viability for up to six months in its dried form and one week after reconstitution. It also allowed interaction with the nasal mucosa, preserving its antimicrobial and anti-inflammatory activities. The developed nasal spray could become a promising formulation in the field of nasal infectious and inflammatory diseases.
由于上呼吸道细菌感染的高频率和严重性，益生菌可能提供一种新的医学方法。我们探索了新菌株BIA的抗菌和抗炎特性，并配制了一种鼻喷雾剂。BIA是从橙皮中分离出来的，并通过16S rRNA基因测序进行分类鉴定。测试了其对[具体细菌名称未给出]、[具体细菌名称未给出]、[具体细菌名称未给出]、[具体细菌名称未给出]和[具体细菌名称未给出]的抗菌活性，同时通过格里斯试验评估其抗炎潜力。对BIA基因组进行了全测序和分析以评估其安全性。BIA被配制在含有益生元和冷冻保护剂的冻干基质中，用聚合物溶液复溶。评估了含有两种羟丙基甲基纤维素（HPMC）和透明质酸的溶液作为重悬介质，并在pH值、粘度和粘膜粘附能力方面进行了比较。验证了制成鼻喷雾剂的BIA的生物活性以及所选制剂的稳定性。BIA抑制人类病原体的生长，并显示出抗炎活性和安全特性。在性能最佳的制剂中，益生菌冻干在10%低聚果糖、0.1%抗坏血酸和0.5%乳糖中，并用1%/的高粘度HPMC复溶。这种组合物确保了益生菌在干燥形式下长达六个月以及复溶后一周的活力。它还允许与鼻黏膜相互作用，保持其抗菌和抗炎活性。所开发的鼻喷雾剂可能成为鼻感染和炎症疾病领域一种有前景的制剂。
